U.S. Communications Stock News

NasdaqGS:CRWV
NasdaqGS:CRWVIT

US Stock Market Today S&P 500 Futures Edge Lower As Inflation And Fed Risks Loom

The Morning Bull - US Market Morning Update Tuesday, Jan, 13 2026 US stock futures are slightly softer this morning, with E-mini S&P 500 contracts down about 0.1%, as investors focus on three pressure points. First, December consumer price data is expected to show headline and core inflation at 2.7% year on year, a reading that will influence how quickly the cost of living is seen to be easing. Second, the 10 year US government bond yield is around 4.2%, reflecting higher borrowing costs for...
NasdaqGM:XNCR
NasdaqGM:XNCRBiotechs

What Xencor (XNCR)'s 2026 XmAb Pivotal Plans and Cash Runway Through 2028 Mean For Shareholders

Xencor recently outlined its 2026 priorities and advancement milestones for its clinical-stage XmAb drug portfolio, highlighting progress across oncology and autoimmune programs, including early anti-tumor activity and tolerability for its lead T-cell engagers. An important takeaway for investors is Xencor’s expectation that its current cash resources should fund research and operations through 2028, supporting multiple planned pivotal studies without near-term financing guidance. We’ll now...
NasdaqGS:FWRG
NasdaqGS:FWRGHospitality

Is First Watch (FWRG) Using Its Back Bay Bar Concept to Redefine Urban Growth Strategy?

First Watch Restaurant Group has recently expanded its New England footprint by opening a 3,100-square-foot restaurant on Boylston Street in Boston’s Back Bay, featuring seating for 130 guests, an outdoor patio, a full bar and locally inspired artwork, alongside its made-to-order breakfast, brunch and lunch menu and Project Sunrise coffee. This Back Bay opening highlights First Watch’s push into dense urban, experience-focused neighborhoods, adding a new proof point for its daytime-only...
NYSEAM:SDEV
NYSEAM:SDEVPharmaceuticals

Why NovaBay Pharmaceuticals (NBY) Is Up 99.3% After Pivoting From Liquidation To Restructuring And Asset Sales

In recent days NovaBay Pharmaceuticals has attracted intense trading interest as it pursued asset sales, preferred stock designations, and leadership changes instead of outright liquidation, while working to maintain its NYSE American listing. This combination of corporate restructuring steps and renewed focus on preserving the public listing has turned the company into a speculative focal point for investors reviewing its remaining options. We’ll now examine how this shift toward...